Total Voting Rights
May 29 2009 - 2:00AM
UK Regulatory
TIDMPYN
RNS Number : 9500S
Phynova Group PLC
29 May 2009
29 May 2009
Phynova Group plc
("the Company")
Total Voting Rights
The Company announces that, pursuant to the requirements of the Disclosure and
Transparency Rules, the total number of voting rights in respect of each class
of share in issue and admitted to trading on AIM at the date of this
announcement is as follows:
+-----------------------------------------+--------------+--------------+
| | Number of | Numbers of |
| | shares in | voting |
| | issue | rights |
+-----------------------------------------+--------------+--------------+
| Ordinary shares of 1p each | 31,522,520 | 31,522,520 |
+-----------------------------------------+--------------+--------------+
| | | |
+-----------------------------------------+--------------+--------------+
For further information, please contact:
+----------------------------------------------------+---------------------+
| Phynova Group PLC | |
+----------------------------------------------------+---------------------+
| Steve Harris (Non-Executive Chairman) | +44 (0) 1993 880700 |
+----------------------------------------------------+---------------------+
| Tony Mills (CEO Phynova Limited) | |
+----------------------------------------------------+---------------------+
| Robert Miller (CEO Phynova China Limited) | |
+----------------------------------------------------+---------------------+
| | |
+----------------------------------------------------+---------------------+
| Nominated Adviser and Broker: | |
+----------------------------------------------------+---------------------+
| John East & Partners Limited, a subsidiary of | +44 (0) 20 7628 |
| Merchant Securities PLC | 2200 |
+----------------------------------------------------+---------------------+
| John East/Simon Clements | |
+----------------------------------------------------+---------------------+
| | |
+----------------------------------------------------+---------------------+
Notes to Editors:
About Phynova
Phynova is a UK company developing new prescription pharmaceuticals derived from
plants used in Chinese medicines. The Company is focused on viral and bacterial
diseases, metabolic diseases and cancer. Phynova's lead product for hepatitis C
has now completed a Phase I/II trial in the US. One further product, for
post-operative ileus, is targeted for entry to the clinic and there are a
further four products in preclinical development.
For further information please visit www.phynova.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRBBGDUSGDGGCI
Phynova (LSE:PYN)
Historical Stock Chart
From Apr 2024 to May 2024
Phynova (LSE:PYN)
Historical Stock Chart
From May 2023 to May 2024
